General Information of Drug (ID: DMQ3C05)

Drug Name
ISIS-APO(a) Drug Info
Indication
Disease Entry ICD 11 Status REF
Coronary artery disease BA80 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMQ3C05

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pelacarsen DMY757D Cardiovascular disease BA00-BE2Z Phase 3 [3]
AMG 890 DM3H0IX Cardiac fibrosis DB98.8 Phase 2 [4]
SLN360 DMVVU4V Hyperlipidemia 5C80.Z Phase 2 [5]
LY3819469 DMUDNNF Elevated Lipoprotein(a) 5C80.1 Phase 2 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apolipoprotein A messenger RNA (LPA mRNA) TTU9LGY APOA_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT02160899) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Patients With High Lipoprotein(a). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
3 Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769.
4 Clinical pipeline report, company report or official report of Amgen.
5 Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308.
6 ClinicalTrials.gov (NCT05565742) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a). U.S.National Institutes of Health.